LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Inicio・Lista de Acciones・Innoviva Inc

Innoviva Inc

Cerrado

SectorSanidad

22.45 1.35

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

21.82

Máximo

22.49

Métricas clave
By Trading Economics
Ingresos	-55M 187M
Ventas	-20M 98M
P/B Media del Sector	3.482 49.701
BPA	0.468
Margen de beneficios	190.415
Empleados	159
EBITDA	-160M 48M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+55.58% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-93M 1.6B
Apertura anterior	21.1
Cierre anterior	22.45

Noticias sobre sentimiento de mercado

By Acuity

50%

148 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

18.57 / 18.75 Soporte y Resistencia

Innoviva Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 may 2026, 22:48 UTC

Adquisiciones, fusiones, absorciones

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 may 2026, 16:49 UTC

Ganancias

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 may 2026, 16:26 UTC

Principales Movimientos del Mercado

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 may 2026, 23:51 UTC

Charlas de Mercado

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 may 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 may 2026, 23:30 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

21 may 2026, 23:30 UTC

Charlas de Mercado

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 may 2026, 22:33 UTC

Adquisiciones, fusiones, absorciones

Conduent to Sell Public Transit Business to Modaxo for $164M

21 may 2026, 21:53 UTC

Ganancias

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 may 2026, 21:02 UTC

Ganancias

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 may 2026, 20:55 UTC

Ganancias

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 may 2026, 20:30 UTC

Acciones populares

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 may 2026, 20:20 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 may 2026, 20:20 UTC

Charlas de Mercado

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 may 2026, 20:20 UTC

Ganancias

Webull 1Q Adj EPS 3c >BULL

21 may 2026, 20:20 UTC

Ganancias

Webull 1Q Rev $159.9M >BULL

21 may 2026, 20:18 UTC

Charlas de Mercado

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 may 2026, 20:18 UTC

Ganancias

Webull 1Q Loss/Shr 4c

21 may 2026, 19:43 UTC

Charlas de Mercado

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 may 2026, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 may 2026, 18:58 UTC

Ganancias

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 may 2026, 18:15 UTC

Charlas de Mercado

Gold Higher For Second Consecutive Day -- Market Talk

21 may 2026, 17:40 UTC

Charlas de Mercado

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 may 2026, 17:04 UTC

Charlas de Mercado

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 may 2026, 17:01 UTC

Ganancias

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 may 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Stellantis Targets Distant but Constructive -- Market Talk

21 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Innoviva Inc previsión

Precio Objetivo

By TipRanks

55.58% repunte

Estimación a 12 Meses

Media 34.6 USD 55.58%

Máximo 46 USD

Mínimo 18 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Innoviva Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

18.57 / 18.75Soporte y Resistencia

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

148 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.